Quanta subsidiary Medolife Rx has reported positive results from a study that assessed the safety and toxicity of a polarised drug candidate to treat Covid-19 patients.

The study was conducted on more than 500 patients in Santo Domingo of the Dominican Republic.

The subjects were administered with the drug Escozine, a polarised solution of the Rhopalurus princeps scorpion peptide owned by Medolife, sublingually four times a day.

After administration, the associated researchers conducted a complete blood count (CBC) of each patient and measured different parameters such as hemoglobin (Hb), hematocrit (HCT) and red blood cells (RBCs) levels.

The assessment did not observe any significant differences before and after administration.

Furthermore, there was no significant change in white blood cells (WBCs), neutrophils, lymphocytes, monocytes, or eosinophils.

The data indicated that the drug candidate is safe and non-toxic.

Medolife CEO Dr Arthur Mikaelian said: “A successful safety study is a pivotal step in the clinical development programme for a new drug candidate and we could not be more enthusiastic about our results.

“While our near-term goal is to work with the Ministry of Environment of The Dominican Republic to bring this drug to market, we are able to use this data in our programmes around the world, including with our submissions to the US Food and Drug Administration.

“While there is significant research that suggests the potential therapeutic benefits of extracted scorpion peptide, when paired with our proprietary polarisation technology that increases efficacy and bioavailability in the body, we believe our product Escozine could be a true breakthrough in the field of medicine with applications in a variety of focus areas and indications.”

In a separate development, Dyadic International, a biotechnology company, announced that it is planning to conduct first-in-human Phase I clinical trial of its vaccine candidate, DYAI-100, in the second half of this year.